DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Therapeutic Potential of Kappa-Opioids Against Cocaine - 1

Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cocaine-Related Disorders

Phase: Phase 1

Status: Completed

Sponsored by: National Institute on Drug Abuse (NIDA)

Official(s) and/or principal investigator(s):
Sharon Walsh, Ph.D., Principal Investigator, Affiliation: Johns Hopkins University


The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.

Clinical Details

Official title: Therapeutic Potential of Kappa-Opioids Against Cocaine

Study design: Primary Purpose: Screening


Minimum age: 21 Years. Maximum age: 50 Years. Gender(s): Both.


Inclusion Criteria: opiate experienced, healthy Exclusion Criteria: physical dependence on opioids, barbiturates or alcohol

Locations and Contacts

Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland 21224 6823, United States
Additional Information

Related publications:

Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl). 2001 Sep;157(2):151-62.

Starting date: July 1996
Last updated: June 23, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017